Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.9500
+0.0200 (2.15%)
At close: Aug 13, 2025, 4:00 PM
0.9500
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:00 AM EDT
Biofrontera Revenue
Biofrontera had revenue of $9.03M in the quarter ending June 30, 2025, with 15.19% growth. This brings the company's revenue in the last twelve months to $39.19M, up 11.20% year-over-year. In the year 2024, Biofrontera had annual revenue of $37.32M with 9.54% growth.
Revenue (ttm)
$39.19M
Revenue Growth
+11.20%
P/S Ratio
0.19
Revenue / Employee
$421,376
Employees
93
Market Cap
9.63M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BFRI News
- 16 hours ago - Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 days ago - Biofrontera Inc. Appoints George Jones as Chief Commercial Officer - GlobeNewsWire
- 9 days ago - Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025 - GlobeNewsWire
- 6 weeks ago - Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment - GlobeNewsWire
- 2 months ago - BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book - GlobeNewsWire
- 3 months ago - Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire